Posts

Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition

on

Incyte acquires Vega Therapeutics for up to $2B to add late‑phase bleeding‑disorder asset VGA039

on

Incyte inks deal with Edison Scientific to train AI through drug discovery

on

Incyte Scores Phase 3 Wins for Povorcitinib in Vitiligo Treatment

on

AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway in Skin Diseases

on

Incyte Receives FDA CRL for Zynyz NSCLC Expansion Due to Issues at Novo Nordisk's Catalent Indiana Facility, Becoming Third Affected Company

on

Incyte's Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection

on

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

on